Ibustar

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ibustar

What is Ibustar?

Ibustar is a medicinal product that belongs to a group of medications known as non-steroidal anti-inflammatory drugs (NSAIDs). Its active ingredient is ibuprofen, which is derived from propionic acid. This medication is primarily used for its ability to reduce inflammation, alleviate pain, and lower body temperature in the event of a fever.

Mechanism of Action

The therapeutic effects of Ibustar are achieved through the inhibition of enzymes called cyclooxygenases (COX-1 and COX-2). These enzymes play a central role in the production of prostaglandins, which are lipid compounds that act as chemical messengers in the body. Prostaglandins are responsible for signaling pain, inducing inflammation, and regulating the body's internal thermostat in the hypothalamus. By reducing the synthesis of these compounds, Ibustar helps to dampen the physiological processes that lead to discomfort and swelling.

Therapeutic Properties

Ibustar is characterized by several key properties:

  • Analgesic: It acts to relieve various types of mild to moderate pain.
  • Antipyretic: It assists in reducing elevated body temperatures during febrile illnesses.
  • Anti-inflammatory: It helps to decrease swelling and redness associated with inflammatory responses.

Composition and Formulations

The core component of Ibustar is ibuprofen. Depending on the specific product variant, it may be formulated as film-coated tablets or as an oral suspension. These formulations are designed to allow the active substance to be absorbed into the bloodstream, where it can then circulate to the affected tissues to exert its effects.

Regulatory References

  1. National Institutes of Health (NIH)
  2. StatPearls

What side effects are possible with Ibustar?

Possible Side Effects and Safety Information

Ibustar (ibuprofen) is associated with a risk profile that is formally documented by government regulatory bodies. The safety information emphasizes potential serious adverse reactions, which often serve as major warnings on the product labeling.

Serious Safety Warnings and Restrictions

Regulatory documents highlight the potential for two life-threatening adverse event categories:

  • Serious Gastrointestinal Events: There is a documented risk of stomach or intestinal bleeding, ulceration, and perforation, which can be fatal. This risk is greater with prolonged use or in certain patient populations.
  • Serious Cardiovascular Thrombotic Events: Use, particularly at high daily doses (at or above 2,400 mg/day), is associated with an increased risk of serious events like myocardial infarction (heart attack) and stroke.

Safety data specifies that the overall risk can be minimized by utilizing the lowest effective dose for the shortest duration necessary for treatment.

Contraindications and Population-Specific Risks

Ibustar is contraindicated (should not be used) in patients with active peptic ulceration or bleeding, those who have experienced severe allergic reactions (e.g., asthma, hives) to aspirin or other NSAIDs, and during the third trimester of pregnancy due to risks to the fetus.

Particular caution is advised for elderly patients and those with pre-existing conditions such as uncontrolled high blood pressure, heart failure, or severe kidney/liver impairment, as these groups face an increased vulnerability to serious side effects.

Documented Adverse Reactions

The most commonly reported adverse reactions include gastrointestinal disturbances (e.g., nausea, vomiting, abdominal pain), headache, and dizziness. Less common but serious reactions documented in official sources include severe allergic reactions, liver dysfunction, kidney problems, and serious skin reactions (e.g., Stevens-Johnson syndrome).

Overdose and Emergency Response

Overdose and when to seek help: Official Regulatory Information for Ibustar

Overdose scope

Field Official Regulatory Statement (Ibuprofen)
Documented overdose presentations: Nausea, vomiting, abdominal pain, drowsiness, lethargy, headache, tinnitus, central nervous system (CNS) depression (e.g., decreased consciousness, coma), convulsions/seizures, hypotension, respiratory depression/apnoea, acute renal failure, metabolic acidosis, haematuria, and little to no urine production (oliguria).
Physiological systems affected (as stated in label): Gastrointestinal tract, Central Nervous System, Renal, Cardiovascular, Respiratory, and Metabolic systems.
Dose-related or exposure-related factors (if applicable): Ingestions exceeding 400 mg/kg carry a risk of multi-organ dysfunction. In children, massive ingestions have induced seizures, apnoea, and coma.
Emergency-response statements (as written in official documents): Immediately contact a Poison Control Center or seek emergency medical attention in the event of an overdose. Do not delay calling for help. The healthcare provider will measure and monitor vital signs and assess the patient's condition.

Official Overdose Management and Classifications

The severity of the overdose is defined as dose-dependent, ranging from mild GI/CNS effects to severe outcomes like shock and acute renal failure. Management is strictly symptomatic and supportive, as regulatory information indicates that no specific antidote is available. Measures like gastric decontamination (e.g., activated charcoal) may be considered early after ingestion, but enhanced elimination (like dialysis) is generally ineffective due to high protein binding. The patient must be monitored for signs of bleeding due to potential platelet inhibition.

Therapeutic Uses of Ibustar

The active ingredient in Ibustar is commonly applied across therapeutic domains where additional symptomatic support is needed to address symptoms related to physical discomfort that interfere with daily functioning. The use of the medication is relevant for managing symptom clusters that may become intense or disruptive in acute situations. It is used to help manage pain from conditions such as headache, toothache, and menstrual cramps (dysmenorrhea), alongside easing the symptoms related to fever and relieving the discomfort of minor arthritis and muscle aches.


Easing Pain, Inflammation, and Fever

Ibustar is commonly used in clinical settings that involve acute or unstable symptom patterns, offering symptomatic support for the pain associated with musculoskeletal conditions like osteoarthritis and sprains, and for managing generalized discomfort during seasonal illness. It provides support that helps ease the overall symptom burden, contributing to improved comfort during periods of heightened symptoms. By assisting with easing the symptoms of localized swelling and stiffness, the medication assists with maintaining functional stability when symptoms are more noticeable, especially in situations marked by temporary physiological imbalance.


Quick Fact: Relief for Episodic Discomfort

The medication is relevant when supportive symptom management is appropriate for conditions characterized by episodic or fluctuating manifestations, and is commonly applied in scenarios where additional management of discomfort is required.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

The eligibility for Ibustar (Ibuprofen) is strictly defined by official regulatory criteria, outlining populations who are permitted, restricted, or absolutely prohibited from use.

Absolute Contraindications (Must Not Use)

Ibustar is strictly contraindicated for patients with known hypersensitivity to Ibuprofen, aspirin, or other NSAIDs, or a history of recurrent peptic ulcer or gastrointestinal haemorrhage. Use is also prohibited for those diagnosed with severe heart failure (NYHA Class IV), severe renal failure, or severe hepatic failure. The drug is contraindicated during the last trimester of pregnancy (after 30 weeks gestation) and for treating peri-operative pain in the setting of CABG surgery.

Age-Related Eligibility

Use is established for adults and adolescents over 12 years of age. The medicine is generally not recommended for children under 12 years for common oral forms. Older adults (aged 60 and above) are eligible but must use caution due to an increased risk of serious gastrointestinal events.

Conditional Use and Restrictions

Use is subject to restrictions in the presence of specific conditions. Patients with uncontrolled hypertension or congestive heart failure (NYHA Class II-III) must avoid high doses (2400 mg/day). Caution is required for individuals with a history of Crohn's disease or Ulcerative Colitis, or non-severe renal/hepatic impairment.

What should I know about interactions with other medicines?

The official interaction profile for Ibustar (Ibuprofen) identifies several critical patterns based on regulatory classification. Co-administration is prohibited with other medicinal products containing ibuprofen or any other Non-steroidal Anti-inflammatory Drug (NSAID), including COX-2 inhibitors. Additionally, the drug is formally contraindicated for treating pain following coronary artery bypass graft (CABG) surgery.

Significant pharmacodynamic interactions increase the documented risk of gastrointestinal (GI) ulceration and bleeding when Ibustar is combined with certain agents. This includes Anticoagulants (like Warfarin), Antiplatelet agents, Oral Corticosteroids, and Selective Serotonin Reuptake Inhibitors (SSRIs). Furthermore, Ibuprofen can diminish the efficacy of agents like ACE inhibitors, ARBs, and Diuretics.

Pharmacokinetic interactions involve the documented reduction of renal clearance for substances such as Methotrexate and Lithium, which can lead to increased plasma concentrations. To minimize interference with the antiplatelet effect of immediate-release low-dose aspirin, regulators mandate a timing separation: Ibuprofen must be administered at least 30 minutes before or 8 hours after the aspirin dose. Regular consumption of three or more alcoholic drinks daily is also documented as increasing the risk of GI bleeding.

Mechanism of Action

Targeting the Cyclooxygenase (COX) Enzymes

The primary mechanism involves the non-selective, reversible inhibition of the Cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. By binding to these enzymes, Ibuprofen suppresses the initial molecular step of the Arachidonic Acid Cascade, which is crucial for manufacturing chemical messengers called prostaglandins. This action fundamentally limits the release of mediators that amplify nociceptive and inflammatory signals.


Dual Modulation of Central and Peripheral Signaling

The resultant reduction in prostaglandins, notably PGE2, drives a dual effect. Centrally, reduced PGE2 concentration in the hypothalamus allows the elevated thermal set-point to reset toward normal, supporting peripheral heat dissipation. Peripherally, the diminished prostaglandin levels prevent the excessive sensitization of nociceptors (pain nerves) at injury sites. This concurrent modulation of both central thermoregulation and peripheral pain signaling defines the drug's physiological influence within these systems.


Constraints of Reversible Mechanism

The interaction is defined as reversible, meaning Ibuprofen's binding to the COX enzymes is temporary and concentration-dependent. This characteristic means that as the drug's concentration declines, the enzyme activity quickly recovers. This is a critical mechanistic constraint that results in a transient functional consequence on enzyme activity, particularly in cells that cannot rapidly synthesize new enzymes.

Dosage and Administration Information

How to Use Ibustar: Official Administration Guidelines

Ibustar (ibuprofen) is administered according to strict protocols to ensure standardized use. The high-level principle governing all administration is to utilize the lowest effective dosage for the shortest duration necessary for the intended purpose.

Official Routes and Dosing Patterns

The medicine is officially approved for systemic use via the oral and intravenous (IV) routes, with topical formulations also available. Oral dosing for acute, short-term use typically ranges from 200 mg to 400 mg per single dose, administered every four to six hours as needed, without exceeding a 1200 mg daily maximum for non-prescription use. For certain chronic conditions like arthritis, the total daily dose may range from 1200 mg up to a maximum of 3200 mg in divided doses.

Contextual and Population-Specific Administration

Oral formulations may be taken with food or milk to help mitigate gastrointestinal complaints. Liquid oral suspensions must be shaken well and measured using the device provided. The intravenous form is reserved for supervised settings and requires dilution before administration, which must proceed as a slow infusion over a minimum of 30 minutes for adults. For pediatric patients, dosing is weight-based, often calculated at 5 –10 mg/kg body weight, not to exceed a 40 mg/kg daily maximum. If a dose is missed, patients are instructed to skip the missed dose and resume the regular schedule, without taking a double dose to compensate.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ibustar


Evidence for Symptomatic Relief of Acute, Mild-to-Moderate Pain

Research exploring how symptoms change over time for acute physical discomfort has involved numerous short-term, randomized controlled trials (RCTs) and comprehensive meta-analyses. These were relevant in trials assessing short-term or episodic symptom patterns for conditions associated with acute or disruptive episodes like headache, dental discomfort, and menstrual cramps. Studies monitored time to first reported changes and assessed patient-reported outcomes describing perceived discomfort on standardized scales.

Studies conducted during periods of increased symptom activity reported data showing patterns related to pain intensity, primarily observed over a short follow-up period, often lasting only a few hours after a single dose. Research describes changes measured during the study period, and these findings contribute to the broader evidence landscape by contextualizing how patients reported their experience during acute episodes. Follow-up durations were limited, as evidence is primarily derived from studies focused on immediate or short-term symptom patterns.

Evidence for Symptomatic Management of Fever (Antipyresis)

Research exploring short-term symptom changes in fever utilized randomized controlled trials (RCTs), particularly in the pediatric population. These studies monitored outcomes linked to systemic or functional imbalance, such as the magnitude of change in body temperature and the time frame during which temperature changes were observed. Findings describe patterns observed in the studies, reporting how outcomes related to physiological strain evolved over defined time intervals.

Data for certain groups, particularly very young infants, remain insufficient. Evidence quality varies across studies due to differences in the initial temperature of the participants and the criteria used to define the state of fever. As the evidence primarily reflects a focus on temporary physiological imbalance, it offers limited insight into managing fever that is persistent or recurs over an extended number of days.


What is Still Uncertain About the Research

Several key research limitations are noted in the evidence landscape. For acute uses, the results apply mainly to a very short timeframe, providing limited context for how symptoms may evolve over several days or weeks. Furthermore, evidence quality varies across studies, particularly for long-term outcomes in chronic conditions like osteoarthritis, where sample sizes were modest for the longest follow-up durations. Comparative evidence against certain newer alternatives is lacking or is still emerging.

Key Studies & References

  1. Ibuprofen Drug Information: MedlinePlus
  2. Ibuprofen: StatPearls [Internet] (NIH/NCBI)
  3. Osteoarthritis: care and management (National Institute for Health and Care Excellence - NICE Guideline [CG177])

Frequently Asked Questions (FAQ)

Common questions about Ibustar (FAQ)


Q: Is there a difference between the over-the-counter and prescription strength versions?

Official product information defines different maximum daily doses based on the product’s classification. Regulatory maximums for non-prescription (over-the-counter) use are lower, typically not exceeding 1200 mg per day. Prescription doses, which are used for certain chronic conditions under medical supervision, may range up to a higher daily maximum.


Q: Is Ibustar the same active ingredient as what's in Advil or Motrin?

Yes, official regulatory documents confirm that the sole active ingredient in Ibustar is ibuprofen. Ibuprofen is also the active medicinal compound found in the brand-name medications Advil and Motrin. These products share the same fundamental purpose as an analgesic (pain reliever) and antipyretic (fever reducer).


Q: Is there a connection between Ibustar and increased blood pressure?

Official safety warnings indicate that Non-steroidal Anti-inflammatory Drugs (NSAIDs), including ibuprofen, have been associated with the development of new high blood pressure (hypertension) or the worsening of pre-existing hypertension. Regulatory documents recommend that individuals with blood pressure concerns discuss the need for monitoring with their healthcare provider during treatment.


Q: What are the signs of a potential kidney issue described in connection with NSAIDs like Ibustar?

Official safety information indicates that serious kidney problems are a documented, though less common, risk. Signs that may suggest a potential kidney issue include the onset of swelling (edema) in the hands, feet, or ankles, or in some cases, blood noted in the urine.


Q: What visual symptoms are sometimes noted as side effects of Ibustar?

Regulatory labeling reports that visual symptoms are rare but can occur. These symptoms include changes such as blurred or diminished vision, scotomata (blind spots), or changes in color vision. Official safety advice states that these symptoms, if they develop, warrant discontinuation of the product and an ophthalmologic examination.


Q: Can Ibustar cause issues with hearing, such as ringing in the ears?

Yes, official side-effect profiles note that hearing issues can occur, particularly tinnitus (a ringing or buzzing in the ears) or hearing loss. These are typically noted as less common side effects, and evidence indicates they are often reversible upon discontinuation of the medication.


Q: Why is there a liquid suspension form of Ibustar for children?

Official regulatory documents state that pediatric dosing for this medication is determined by the child’s body weight. The liquid suspension form is used because it allows for the precise, measured administration required for weight-based dosing, unlike a solid tablet.


Q: Is the active ingredient in Ibustar approved for use in other countries?

Yes, the active ingredient, ibuprofen, is subject to standardized regulatory oversight. Official documentation confirms that the substance is widely approved and used across major regulatory jurisdictions globally, including those governing the United States and the European Union.


Q: What are some of the non-pain conditions that Ibustar has been studied for?

Official regulatory indications confirm that beyond treating pain and fever, the medication is approved for use in managing symptoms associated with certain inflammatory disorders. Examples include the symptomatic management of juvenile arthritis and rheumatoid arthritis.


Q: Is Ibustar generally safe for use while breastfeeding?

Information from official regulatory bodies indicates that only small amounts of ibuprofen pass into breast milk. Ibuprofen is generally regarded as one of the compatible options during breastfeeding because the minimal dose the infant receives is far below the therapeutic dose used in infants.


Q: Why must Ibustar be avoided if a person has had an allergic reaction to aspirin?

Official safety information designates the use of Ibustar as contraindicated in these circumstances due to the documented risk of cross-reactivity. This means that individuals who have experienced a severe allergic reaction to aspirin (like asthma or hives) are at risk of experiencing a similar reaction to ibuprofen.


Q: Can Ibustar affect fertility or egg release, as noted in some studies?

Official regulatory documents indicate that the prolonged or high-dose use of the drug may reversibly affect ovulation (the release of an egg). This temporary effect could potentially make conception more difficult while a person is actively taking the medication.


Q: Is it normal for a person's hands or feet to swell while taking Ibustar?

Official safety documents report that fluid retention and edema (swelling) have been observed in some individuals taking NSAIDs. Regulatory caution is particularly advised for patients with pre-existing conditions like heart failure.


Q: What are the reported signs of stomach bleeding linked to NSAID use?

Official safety warnings highlight the potential for serious gastrointestinal bleeding. Patient-perceptible signs may include persistent stomach pain, vomiting blood, or noticing that the stool is black, sticky, and tar-like.


Q: What should a person know about using Ibustar for menstrual cramps?

Regulatory documents list Primary Dysmenorrhea, or menstrual cramps, as one of the specific temporary pain conditions for which the medication is indicated for symptomatic relief. Studies exploring changes in symptoms were relevant in trials assessing short-term episodic pain patterns.


Q: Can Ibustar be used for tension headaches?

Regulatory documents list headache as one of the minor aches and pains the medication is indicated to relieve. Research evidence for acute pain includes studies that assessed short-term episodic symptom patterns for headache relief.


Q: Can Ibustar be used for pain after a tooth extraction?

Regulatory documents list toothache as one of the minor aches and pains the medication is indicated to relieve. The research overview mentions short-term trials relevant to dental discomfort and pain.


Q: Is Ibustar typically used for short-term or long-term issues?

Regulatory documents state that the general principle for use is to use the lowest effective dose for the shortest duration possible. The treatment duration ranges from short-term relief for temporary pain to longer-term management of certain chronic inflammatory conditions.


Q: Is Ibustar only available with a prescription?

According to official regulatory information, the drug is available for both prescription and non-prescription use. It is available without a prescription for lower daily dosages, but higher doses or use for chronic conditions require a prescription.


Q: Are there any general cautions about using Ibustar with alcohol?

Official regulatory documents warn that the risk of serious gastrointestinal bleeding is increased by the regular consumption of alcohol. This specific warning applies to individuals who consume three or more alcoholic drinks daily.


Q: Is there a list of certain types of antidepressants that interact with Ibustar?

Official interaction profiles specifically note an increased risk of gastrointestinal bleeding when ibuprofen is combined with Selective Serotonin Reuptake Inhibitors (SSRIs). This interaction is classified as a significant pharmacodynamic interaction by regulators.


Q: Are there age restrictions for who can or cannot use the liquid suspension form of Ibustar?

Pediatric use is generally restricted to certain age and weight criteria. While common oral forms are generally not recommended for children under 12, the liquid suspension is specifically designed for weight-dosed administration in younger patients, often requiring a minimum age or weight as defined by the product label.

How should Ibustar be stored and disposed of?

Official Storage and Disposal Requirements

The storage and disposal of Ibustar (Ibuprofen) must adhere strictly to the conditions mandated in government regulatory labeling to maintain stability and safety.

Storage Conditions

Requirement Official Regulatory Statement
Temperature Store typically below 25 C or 30 C; liquid forms must be kept from freezing.
Protection Store in the original container and outer carton to protect from light and moisture; bottles must be kept tightly closed.
Child Safety Must be stored out of the sight and reach of children (a mandatory requirement).

Disposal Instructions

Any unused or expired product must be handled as pharmaceutical waste. Official instructions state to return any left over tablets to the Pharmacist or dispose of the product in accordance with local requirements. Medicine must not be discarded via household waste or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ibustar found in:

A-Z Index: